BioSpace News Archive

Parvizi Surgical Innovation, LLC (PSI) is pleased to announce an investment and partnership with Coracoid Solutions, LLC (CCS), an early-stage medical device company focused on sports medicine procedures.

AZTherapies, Inc. , a biopharmaceutical company in advanced clinical trials to treat neuroinflammatory diseases, today announced the dosing of the first patient in its Phase 2a clinical trial examining the safety and efficacy of ALZT-OP1a in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS). ALZT-OP1a is the company’s proprietary inhaled formulation of cromolyn, engineered to improve blood brain barrier permeability and bioa

SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications, today announced that it has received approval of its Investigational Medicinal Product Dossier (IMPD) from the French regulatory authority,

Avricore Health Inc.(TSXV: AVCR, OTC: AVCRF) (“Avricore” or the “Company”) a leader in pharmacy-based point-of-care testing solutions, plans to offer its HealthTab™ system as a stand-alone service to improve COVID19 case reporting.

Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer R.Ph., President and Chief Executive Officer, and Matt D’Onofrio, Chief Business Officer, are scheduled to participate virtually in the H.C. Wainwright 22nd Annual Global Investment Conference taking place September 14 – September 16, 2020. Event: H.C. Wainwright 22nd Annua

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its licensing partner, REGENXBIO Inc. (Nasdaq: RGNX), has dosed the first patient in its Phase 2 clinical trial to evaluate the suprachoroidal delivery of RGX-314, an adeno-associated virus (AAV) gene therapy, using Clear

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com [09-September-2020] TORONTO , Sept. 9, 2020 /PRNewswire/ -- Aleafia Health Inc. (TSX: AH, OTC: ALEAF), a Canadian cannabis health and wellness company, today announced that Geoffrey Benic , CEO, w

Oncomfort, the Belgian inventor of and leader in Digital SedationTM - a method for relieving patients’ pain and anxiety without medication - today announces the completion of a €10 million Series A funding round co-led by two prominent institutional investors: Debiopharm and Crédit Mutuel Innovation.

Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster and more affordable, today announced that Dr. Martin Madaus will be joining as the company’s Chief Operations Officer to assist in the rapid expansion of Sherlock in the next 12 months. Dr. Madaus brings to Sherl

Alexion Announces Upcoming Data Presentations at MSVirtual2020, the 8th Joint ACTRIMS – ECTRIMS Meeting - Accepted abstracts include data assessing the long-term efficacy and safety of SOLIRIS ® (eculizumab) in neuromyelitis optica spectrum disorder (NMOSD) - - Data from 11 abstracts demonstrate Alexion’s commitment to continuing to advance the understanding of the burden of NMOSD for patients and the efficacy and safety of SOLIRIS in real-world sett